Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Kim Reiss Binder, MD
CONTACT
Alex Torres
CONTACT
Lead
Abramson Cancer Center at Penn Medicine
With
This is an open-label, phase II study of saruparib in patients with locally advanced or metastatic solid tumors that are HRDsig+ by FoundationOneCDx (Foundation Medicine, Inc). Patients in Cohort A must also have a pathogenic germline or somatic variant in BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D or BARD1. The primary endpoint is overall response rate in Cohort A.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted